The Role of Budesonide in Adults and Children with Mild‐to‐Moderate Persistent Asthma

References

• National Institutes of Health: National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. NIH, Bethesda, MD 1997, (publication No. 97‐4051)
   Google Scholar
• National Institutes of Health: National Heart, Lung, and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH, Bethesda, MD 2002, (publication No. 02‐3659)
   Google Scholar
• Mannino D M, Homa D M, Pertowski C A, Ashizawa A, Nixon L L, Johnson C A, Ball L B, Jack E, Kang D S. Surveillance for Asthma—United States, 1960–1995. Mor Mortal Wkly Rep CDC Surveill Summ 1998; 47(1)1–27
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention: National Center for Health Statistics. New Asthma Estimates: Tracking, Prevalence, Healthcare, and Mortality Fact Sheet. 2001, (released 10/05/2001)
   Google Scholar
• American Lung Association: Epidemiology and Statistics Unit: Best Practices and Program Services. Trends in Asthma Morbidity and Mortality 2002. American Lung Association. 2002
   Google Scholar
• Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, Sovijärvi A, Stenius‐Aarniala B, Svahn T, Tammivaara R, Laitinen L A. Comparison of a β2‐agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325(6)388–392, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Selroos O, Sovijärvi A, Stenius‐Aarniala B, Svahn T, Tammivaara R, Laitinen L A. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331(11)700–705, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Selroos O, Pietinalho A, Löfroos A‐B, Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest 1995; 108(5)1228–1234, Permission granted by Chest, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Lofdahl C G, Postma D S, Tattersfield A E, O'Byrne P, Barnes P J, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) International Study Group. N Engl J Med 1997; 337(20)1405–1411, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Tal A, Simon G, Vermeulen J H, Petru V, Cobos N, Everard M L, de Boeck K. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002; 34(5)342–350, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Pearlman D S, Stricker W, Weinstein S, Gross G, Chervinsky P, Woodring A, Prillaman B, Shah T. Inhaled salmeterol and fluticasone: a study comparing monotherapy in asthma. Ann Allergy Asthma & Immun 1999; 82(3)257–265
   PubMed Web of Science ®Google Scholar
• Shapiro G, Lumry W, Wolfe J, Given J, White M V, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161(2 Pt 1)527–534, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Edsbäcker S, Szefler S J. Glucocorticoid pharmacokinetics: principles and clinical applications. Topical Inhaled Glucocorticoids in Asthma: Mechanisms and Clinical Actions, R P Schleimer, W W Busse, P M O'Byrne. Marcel Dekker, New York 2000; 381–445
   Google Scholar
• Pedersen S, O'Byrne P. A Comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52(Suppl. 39)1–34, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Miller‐Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26(7)623–630
   PubMed Web of Science ®Google Scholar
• Miller‐Larsson A, Jansson P, Runström A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 2000; 162(4 Pt 1)1455–1461
   PubMed Web of Science ®Google Scholar
• Thorsson L, Thunnisen F BJM, Korn S, Carlshaf A, Edsbäcker S, Wouters E FM. Formation of Fatty Acid Conjugates of Budesonide in Human Lung Tissue in vivo. Am J Respir Crit Care Med 1998; 157(Suppl. 3)A404
   Google Scholar
• Edsbäcker S, Brattsand R. Budesonide fatty‐acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy & Asthma Immun 2002; 88(6)609–616
   PubMedGoogle Scholar
• Hvizdos K M, Jarvis B. Budesonide inhalation suspension. A review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000; 60(5)1141–1178, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Szefler S, Eigen H. Budesonide inhalation suspension: A nebulized corticosteroid persistent asthma. J Allergy Clin Immunol 2002; 109(4)730–742, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Melamed J, Beaucher W. A prospective evaluation of the adequacy of peak inspiratory flow rates and validation of the Turbutester score in asthmatic individuals with “low” peak expiratory flow rates: Implications for dry powder inhalers. J Allergy Clin Immunol 2003; 111: 648–650, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Campbell L M, Gooding T N, Aitchison W R, Smith N, Powell J A. Initial loading (400 µg twice daily) versus static (400 µg Nocte) dose budesonide for asthma management. PLAN research group. Int J Clin Pract 1998; 52(6)361–370, Permission granted by International Journal of Clinical Practice, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Jones A H, Langdon C G, Lee P S, Lingham S A, Nankani J P, Follows R MA, Tollemar U, Richardson P DI. Pulmicort® Turbohaler® once daily as initial prophylactic therapy for asthma. Respir Med 1994; 88(4)293–299, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kemp J, Wanderer A A, Ramsdell J, Southern D L, Weiss S, Aaronson D, Grossman J. Rapid onset of control with budesonide turbuhaler in patients with mild‐to‐moderate asthma. Ann Allergy & Asthma Immun 1999; 82(5)463–471
   PubMedGoogle Scholar
• McFadden E R, Casale T B, Edwards T B, Kemp J P, Metzger W J, Nelson H S, Storms W W, Neidl M J. Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma. J Allergy Clin Immunol 1999; 104(1)46–52, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O. A double‐blind, placebo controlled, parallel group, multi‐centre dose–response study of Pulmicort® (budesonide) Turbuhaler® in Japanese patients with mild or moderate asthma. Am J Respir Crit Care Med 1996; 153(4 Pt 2)A339
   Google Scholar
• Boe J, Rosenhall L, Alton M, Carlsson L‐G, Carlsson U, Hermansson B‐A, Hetta L, Kiviloog J, Karlson B W, Lundbäck B, Martinsson J‐E, Nemcek K, Nemcek V. Comparison of dose–response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthma. Allergy 1989; 44(5)349–355, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Adams N, Bestall J, Jones P. Budesonide at different doses for chronic asthma (Cochrane Review). Cochrane Database Syst Rev 2001; 4: CD003271, [PUBMED], [INFOTRIEVE]
   Google Scholar
• Bousquet J, Ben‐Joseph R, Messonier M, Alemao E, Gould A L. A meta‐analysis of the dose–response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002; 24(1)1–20, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Banov C H, Howland WC I, Lumry W R. Once‐daily budesonide via turbuhaler improves symptoms in adults with persistent asthma. Ann Allergy & Asthma Immun 2001; 86(6)627–632
   PubMedGoogle Scholar
• Chisolm S L, Dekker F W, Knuistingh Neven A, Petri H. Once‐daily budesonide in mild asthma. Respir Med 1998; 92: 421–425, [CROSSREF]
   PubMedGoogle Scholar
• McFadden E R, Casale T B, Edwards T B, Kemp J P, Metzger W J, Nelson H S, Storms W W, Neidl M. Administration of budesonide once daily by means of turbuhaler in subjects with stable asthma. J Allergy Clin Immunol 1999; 104: 46–52, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Selroos O, Edsbäcker S, Hultquist C. Once‐daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. Pulm Pharmacol Ther 2003, (submitted 2003)
   Google Scholar
• Venables T L, Addlestone M B, Smithers A J, Blagden M D, Weston D, Gooding T, Carr E P, Follows R MA. A comparison of the efficacy and patient acceptability of once daily budesonide via turbuhaler and twice daily fluticasone propionate via a disc‐inhaler at an equal dose of 400 µg in adult asthmatics. Br J Clin Res 1996; 7: 15–32
   Google Scholar
• Pincus D J, Szefler S J, Ackerson L M, Martin R J. Chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1995; 95: 1172–1178, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pincus D J, Humeston T R, Martin R J. Further studies on the chronotherapy of asthma with inhaled steroids: the effect of dosage timing on drug efficacy. J Allergy Clin Immunol 1997; 100: 771–774, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Chanez P, Karlstrom R, Godard P. High or standard initial dose of budesonide to control mild‐to‐moderate asthma?. Eur Respir J 2001; 17(5)856–862, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Pirozynski M, Kulaga Z, Karlström R. Pulmicort® (Budesonide) Turbuhaler® in mild to moderate asthma: comparison of initial high dose, constant low dose and placebo. Am J Respir Crit Care Med 1996; 153: A343
   PubMedGoogle Scholar
• Agertoft L, Pedersen S. Effects of long‐term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88(5)373–381, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Baker J W, Mellon M, Wald J, Welch M, Cruz‐Rivera M, Walton‐Bowen K. A multiple‐dosing, placebo‐controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999; 103(2)414–421, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Szefler S, Weiss S, Tonascia A, Adkinson N F, Bender B, Cherniack R. Long‐term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000; 343(15)1054–1063, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kemp J P, Skoner D P, Szefler S J, Walton‐Bowen K, Cruz‐Rivera M, Smith J A. Once‐daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy & Asthma Immun 1999; 83(3)231–239
   PubMed Web of Science ®Google Scholar
• Mellon M. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999; 104(No. 4 Pt 2)S191–S199
   PubMedGoogle Scholar
• Shapiro G, Mendelson L, Kraemer M J, Cruz‐Rivera M, Walton‐Bowen K, Smith J A. Efficacy and safety of budesonide inhalation suspension (pulmicort respules) in young children with inhaled steroid‐dependent, persistent asthma. J Allergy Clin Immunol 1998; 102(5)789–796, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Pedersen S, Ramsgaard Hansen O. Budesonide treatment of moderate and severe asthma in children: a dose–response study. J Allergy Clin Immunol 1995; 95(1 Pt 1)29–33, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Shapiro G. Once‐daily inhaled corticosteroids in children with asthma: nebulisation. Drugs 1999; 58(4)43–49, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Campbell L M, Bodalia B, Gogbashian C A, Gunn S D, Humphreys P J, Powell J P. Once‐daily budesonide: 400 µg once daily is as effective as 200 µg Twice daily in controlling childhood asthma. Int J Clin Pract 1998; 52(4)213–219, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Jónasson G, Carlsen K‐H, Blomqvist P. Clinical efficacy of low‐dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. Eur Respir J 1998; 12(5)1099–1104, [CROSSREF]
   PubMedGoogle Scholar
• Möller C, Strömberg L, Oldaeus G, Arweström E, Kjellman M. Efficacy of once‐daily versus twice‐daily administration of budesonide by turbuhaler® in children with stable asthma. Pediatr Pulmonol 1999; 28(5)337–343, [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shapiro G G, Mendelson L M, Pearlman D S. Once‐daily budesonide inhalation powder (pulmicort turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids. Ann Allergy & Asthma Immun 2001; 86(6)633–640
   PubMedGoogle Scholar
• Jónasson G, Carlsen K‐H, Jonasson C, Mowinckel P. Low‐dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000; 55(8)740–748, [CROSSREF]
   PubMedGoogle Scholar
• Lipworth B J. Systemic effects of inhaled corticosteroid therapy: a systematic review and meta‐analysis. Arch Intern Med 1999; 159(9)941–955, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Campbell L M. Once‐daily Inhaled Corticosteroids in mild to Moderate Asthma: Improving Acceptance of Treatment. Drugs 1999; 58(suppl. 4)25–33, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Busse W W, Chervinsky P, Condemi J, Lumry W R, Petty T L, Rennard S, Townley R G. Budesonide delivered by turbuhaler is effective in a dose‐dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101(4 Pt 1)457–463, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Selroos O, Backman R, Forsén K‐O, Löfroos A‐B, Niemistö M, Pietinalho A, Äikäs C, Riska H. Local side‐effects during 4‐year treatment with inhaled corticosteroids—a comparison between pressurized metered‐dose inhalers and Turbuhaler®. Allergy 1994; 49(10)888–890, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Clark D J, Grove A, Cargill R I, Lipworth B J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51(3)262–266, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Aaronson D, Kaiser H, Dockhorn R, Findlay S, Korenblat P, Thorsson L, Källén A. Effects of budesonide by means of the turbuhaler on the hypothalmic–pituitary–adrenal axis in asthmatic subjects: a dose–response study. J Allergy Clin Immunol 1998; 101(3)312–319, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cumming R G, Mitchell P, Leeder S R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337(1)8–14, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Garbe E, Suissa S, LeLorier J. Association of inhaled corticosteroid use with cataract extraction in elderly patients. JAMA 1998; 280(6)539–543, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jick S, Vasilakis‐Scaramozza C, Maier W. The risk of cataract among users of inhaled steroids. Epidemiology 2001; 12(2)229–234, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Löfdahl C‐G, Laitinen L A, Schouten J P, Postma D, Pride N B, Ohlsson S V. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340(25)1948–1953, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Duh M‐S, Walker A M, Lindmark B, Laties A M. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy & Asthma Immun 2000; 85(5)356–361
   PubMedGoogle Scholar
• Ebeling P R, Erbas B, Hopper J L, Wark J D, Rubinfeld A R. Bone mineral density and bone turnover in asthmatics treated with long‐term inhaled or oral glucocorticoids. J. Bone Miner Res 1998; 13(8)1283–1289, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Tattersfield A E, Town G I, Johnell O, Picado C, Aubier M, Braillon P, Karlström R. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non‐corticosteroid treatment for two years. Thorax 2001; 56(4)272–278, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long‐term inhaled steroids. Chest 1994; 105(6)1722–1727, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Luengo M, del Rio L, Pons F, Picado C. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case‐control study. Eur Respir J 1997; 10(9)2110–2113, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Norjavaara E, Gerhardsson de Verdier M. Normal pregnancy outcomes in a population‐based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003, in press
   Google Scholar
• Ericson A, Källén B. Use of drugs during pregnancy—unique Swedish registration method that can be improved. Inf Swedish Med Prod Agency 1999; 1: 1–7
   Google Scholar
• Meyer R J. Supplemental New Drug Application for Changes to the Pregnancy Subsection of the Precautions Section Related to a Change in the Pregnancy Category for Pulmicort Turbuhaler® “C” to “B”. AstraZeneca LP. US Food and Drug Administration, Department of Health and Human Services. 2001
   Google Scholar
• Scott M B, Skoner D P. Short‐term and long‐term safety of budesonide inhalation suspension in infants and young children with persistent asthma. J Allergy Clin Immunol 1999; 104(4 Pt 2)S200–S209
   PubMedGoogle Scholar
• Bisgaard H, Pedersen S, Damkjær Nielsen M, Østerballe O. Adrenal function in asthmatic children treated with inhaled budesonide. Acta Paediatr Scand 1991; 80(6)213–217, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Division of Pulmonary Drug Products. Class Labeling for Intranasal and Orally Inhaled Corticosteroid‐Containing Drug Products Regarding the Potential for Growth Suppression in Children. US Food and Drug Administration, Center for Drug Evaluation and Research. 1998
   Google Scholar
• Brand P LP. Inhaled corticosteroids reduce growth. Or do they?. Eur Respir J 2001; 17(2)287–294, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Agertoft L, Pedersen S. Short‐term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J 1997; 10(7)1507–1512, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Bisgaard H. Systemic activity of inhaled topical steroid in toddlers studied by knemometry. Acta Paediatr 1993; 82(12)1066–1071, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Wolthers O D, Pedersen S. Growth of asthmatic children during treatment with budesonide: a double blind trial. BMJ 1991; 303(6795)163–165, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Heuck C, Wolthers O D, Kollerup G, Hansen M, Teisner B. Adverse effects of inhaled budesonide (800 µg) on growth and collagen turnover in children with asthma: a double‐blind comparison of once‐daily versus twice‐daily administration. J Pediatr 1998; 133(5)608–612, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Pedersen S. Do inhaled corticosteroids inhibit growth in children?. Am J Respir Crit Care Med 2001; 164(4)521–535, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Effect of long‐term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343(15)1064–1069, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Norjavaara E, Gerhardsson de Verdier M, Lindmark B. Reduced height in swedish men with asthma at the age of conscription for military service. J Pediatr 2000; 137(1)25–29, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Norjavaara E, Gerhardsson de Verdier M, Lindmark B. Asthma and adult registered height during maternity. Am J Respir Crit Care Med 2000; 161: A744
   Google Scholar
• Merkus P JFM, van Essen‐Zandvliet E EM, Duiverman E J, van Houwelingen H C, Kerrebijn K F, Quanjer P H. Long‐term effect of inhaled corticosteroids on growth rate in adolescents in asthma. Pediatrics 1993; 91(6)1121–1126, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sharek P J, Bergman D A. The effect of inhaled steroids on the linear growth of children with asthma: a meta‐analysis. Pediatrics 2000; 106(1)E8, [PUBMED], [INFOTRIEVE], [CROSSREF]
   Web of Science ®Google Scholar
• Szefler S, Fitzpatrick S, Cruz‐Rivera M, Lyzell E. Lack of cataracts and other localized adverse events in children treated with nebulized pulmicort respules™ (budesonide inhalation suspension). Am J Respir Crit Care Med 2001; 163(5)A589
   Google Scholar
• Turpeinen M, Kari O, HEICA Study Group. No changes in intraocular pressure and no posterior subcapsular opacities in children treated for 18 months with budesonide turbuhaler®. Am J Respir Crit Care Med 2001; 163(5)A851
   Google Scholar
• Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long‐term treatment with inhaled budesonide. Am J Respir Crit Care Med 1998; 157(1)178–183, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• König P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, Johnson L, Allen S. Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Pediatr 1993; 122: 219–226
   PubMed Web of Science ®Google Scholar
• Wolthers O D, Riis B J, Pedersen S. Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide. Pediatr Pulmonol 1993; 16(6)341–346, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Salvatoni A, Nosetti L, Broggini M, Nespoli L. Body composition and growth in asthmatic children treated with inhaled steroids. Ann Allergy & Asthma Immun 2000; 85(3)221–226
   PubMedGoogle Scholar
• Osterman K, Carlholm M, Ekelund J, Kiviloog J, Nikander K, Nilholm L, Salomonsson P, Strand V, Venge P, Zetterström O. Effect of 1 year daily treatment with 400 µg budesonide (Pulmicort® Turbuhaler®) in newly diagnosed asthmatics. Eur Respir J 1997; 10(10)2210–2215, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Pauwels R A, Busse W W, O'Byrne P M, Pedersen S, Tan W C, Chen Y‐Z, Ohlsson S V, Ullman A. The inhaled steroid treatment as regular therapy in early asthma (START) study: rationale and design. Control Clin Trials 2001; 22(4)405–419, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMedGoogle Scholar
• Pauwels R A, Pedersen S, Busse W W, Tan W C, Chen Y‐Z, Ohlsson S V, Ullman A, Lamm C J, O'Bryne P M, on behalf of the START Investigators Group. Early intervention with budesonide in mild persistent asthma. Lancet 2003; 361(9363)1071–1076, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar